Editas Medicine (EDIT) Cash & Equivalents (2015 - 2025)

Editas Medicine (EDIT) has reported Cash & Equivalents for 11 consecutive years, with $146.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 11.48% year-over-year to $146.6 million; the TTM figure through Dec 2025 stood at $146.6 million (up 11.48% YoY), while the FY2025 annual figure was $146.6 million, up 11.48% from the prior year.
• Cash & Equivalents eased to $146.6 million in Q4 2025 per EDIT's latest filing, from $165.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $354.9 million in Q1 2021 and bottomed at $64.4 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $169.8 million across 5 years, with a median of $144.1 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 70.82% — and 2025, when it jumped 114.99%.
• Editas Medicine's Cash & Equivalents stood at $203.5 million in 2021, then slumped by 30.46% to $141.5 million in 2022, then decreased by 12.63% to $123.7 million in 2023, then rose by 6.38% to $131.5 million in 2024, then rose by 11.48% to $146.6 million in 2025.
• Business Quant data shows EDIT's Cash & Equivalents at $146.6 million in Q4 2025, $165.6 million in Q3 2025, and $138.5 million in Q2 2025.